Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00611728 · ClinicalTrials.gov registry record · Phase 1

Ph I SU011248 + Irinotecan in Treatment of Pts w MG

A Phase 1 study, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target

NCT00611728: Completed Phase 1 study, sponsored by Duke University.

NCT00611728 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00611728, a Phase 1 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

Primary Objectives To determine maxi tolerated dose \& dose limiting toxicity of SU011248 + Irinotecan in recurrent MG pts not on EIAEDs To characterize safety \& tolerability of SU011248 + Irinotecan among pts w recurrent MG Secondary Objectives To evaluate pharmacokinetic profile of SU011248 \& Irinotecan when co-administered in pts w MG To evaluate anti-tumor activity of SU011248 + Irinotecan

Interventions

  • DRUG SU011248 & Irinotecan

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2008-03
Est. Completion 2010-09
Phase Phase 1
Duke University

1,725 total trials

What the finished NCT00611728 record still lists

NCT00611728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 1 intervention - of which SU011248 & Irinotecan is the first listed.

NCT00611728 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00611728 about?

NCT00611728 is a clinical study titled "Ph I SU011248 + Irinotecan in Treatment of Pts w MG". Primary Objectives To determine maxi tolerated dose \& dose limiting toxicity of SU011248 + Irinotecan in recurrent MG pts not on EIAEDs To characterize safety \& tolerability of SU011248 + Irinotecan among pts w recurrent MG Secondary Objectives To evaluate pharmacokinetic profile of SU011248 \& Ir...

What is the current status of trial NCT00611728?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-03. Estimated completion is 2010-09.

What interventions are being tested in trial NCT00611728?

The interventions under investigation include: SU011248 & Irinotecan (DRUG).

Who is sponsoring clinical trial NCT00611728?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00611728's enrollment target sits among peer trials

25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00611728, the US trial registry maintained by the National Library of Medicine. NCT00611728 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.